TABLE 5

Pharmacokinetics of AQ and DAQ in the present and previous studies

Subject(s)No. of subjectsSampling period (h)Dosage regimenPK result (±SD)Reference
AQDAQ
Cmax (ng/ml)Tmax (h)T1/2 (h)Cmax (ng/ml)Tmax (h)T1/2 (h)
Adult patients6336Single oral dose for 3 daysa261 ± 15.10.75 ± 0.278.65 ± 1.74753 ± 17248.0213 ± 1.33Present study
Healthy volunteer124Single oral dose for 1 dayb2582.00NAd1,1382.00NA7
Healthy volunteers31,440Single oral dose for 1 daya47.6 ± 14.80.58 ± 0.142.07 ± 1.29802 ± 5010.83 ± 0.29114 ± 77.78
Healthy volunteer1168Single oral dose for 1 dayb11.21.0014.58222.0014910
Healthy volunteers13480Single oral dose for 1 dayb29.2 ± 10.92.32 ± 1.165.50 ± 4.10269 ± 70.83.68 ± 1.85241 ± 14711
Healthy volunteers796Single oral dose for 1 dayb32.0 ± 3.000.50 ± 0.035.20 ± 1.70181 ± 26.03.40 ± 0.80NA13
Pediatric patients12672Single oral dose for 3 daysc618–1,45472NA575–3,94072NA14
Healthy volunteers324Single oral dose for 1 dayb225118.611,001 ± 3542 ± 119 ± 516
Healthy volunteers231,440Single oral dose for 1 dayc61.7 ± 24.81.44 ± 1.112.2 ± 1.1973 ± 5111.7 ± 0.77224 ± 10217
  • a Amodiaquine administered as a fixed-dose combination (AQAS).

  • b Amodiaquine administered as monotherapy (AQ).

  • c Amodiaquine administered as a non-fixed-dose combination (AQ-AS).

  • d NA, not available.